Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 7/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448462 | 0.94 | SYK (0.38) | SYKRAF1BRAFAVPR1BEGFR | |
| SCHEMBL3448330 | 0.92 | AXL (0.36) | SYKEGFRAXL | |
| SCHEMBL3448963 | 0.90 | SYK (0.36) | SYKRAF1BRAFEGFRAXL | |
| SCHEMBL3448714 | 0.90 | SYK (0.38) | SYKEGFRAXL | |
| SCHEMBL3448651 | 0.89 | SYK (0.48) | SYKEGFRAXL | |
| SCHEMBL3450088 | 0.89 | SYK (0.40) | SYKBRAFEGFRKDRMAP3K8 | |
| SCHEMBL3449131 | 0.89 | SYK (0.37) | SYKEGFRAXL | |
| SCHEMBL3447298 | 0.88 | RAF1 (0.38) | SYKRAF1BRAFEGFRAXL | |
| SCHEMBL3449285 | 0.88 | EGFR (0.42) | SYKBRAFEGFRAXLKDR | |
| SCHEMBL3456772 | 0.87 | SYK (0.38) | SYKEGFRAXLWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | SYK 804/4885RAF1 2448/4885BRAF 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.